Kezdőlap | A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

2012.05.31 11:54

Gyógyszer: Tasocitinib (CP-690,550) - Janus kináz inhibitor
Alkalmazás: tabletta
Középsúlyos-súlyos psoriasis (legalább 10% testfelszín érintettség)
18 évet betöltött életkor

Vissza

Minden ami psoriasis

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Menü

Keresés

Elérhetőség